Professional stakeholders' expectations for the future of community pharmacy practice in England : a qualitative study

Paloumpi, Evgenia and Ozieranski, Piotr and Watson, Margaret C and Jones, Matthew D (2023) Professional stakeholders' expectations for the future of community pharmacy practice in England : a qualitative study. BMJ open, 13 (10). e075069. ISSN 2044-6055 (https://doi.org/10.1136/bmjopen-2023-075069)

[thumbnail of Paloumpi-etal-BMJO-2023-Professional-stakeholders-expectations-for-the-future-of-community-pharmacy-practice-in-England]
Preview
Text. Filename: Paloumpi_etal_BMJO_2023_Professional_stakeholders_expectations_for_the_future_of_community_pharmacy_practice_in_England.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo

Download (1MB)| Preview

Abstract

Objectives To explore the views of professional stakeholders on the future of community pharmacy services in England. Specific objectives related to expectations of how community pharmacy services will be provided by 2030 and factors that will influence this. Design Qualitative, using semistructured interviews in person or via telephone/Skype. The topic guide was informed by a recent policy review that used the Walt and Gilson policy framework. Transcripts were analysed using inductive thematic analysis. Setting England. Participants External stakeholders were representatives of non-pharmacy organisations, including policy-makers, commissioners and representatives of healthcare professions. Internal stakeholders were community pharmacists or pharmacy organisation representatives. Interviewees were identified using stakeholder mapping Results In total, 25 interviews were completed (7 external stakeholders and 18 internal stakeholders, of which 10 were community pharmacists). Community pharmacy was recognised as having a key role in expanding health system capacity (‘…pharmacy is the obvious person to take on those roles…’), particularly for long-term condition management (eg, adherence, reducing polypharmacy, monitoring), urgent care (eg, minor illnesses) and public health (including mental health). For these contributions to be developed and optimised, greater integration and collaboration with general practices will be needed (‘…there is no room for isolationism in pharmacy anymore…’), as well as use of technology in a patient-centred way and full access to health records. These changes will require workforce development together with appropriate commissioning and contractual arrangements. Community pharmacy is currently undervalued (‘…the complete misunderstanding by senior Government officials is very scary’) and recent investment in general practice pharmacists rather than community pharmacy was seen as a missed opportunity. Conclusions Community pharmacy as a sector could and should be developed to increase health service capacity to address its current challenges. Numerous modifications are required from a range of stakeholders to create the environment in which these changes can occur.